Recent News About Hesperos and Human-on-a-Chip Technology

Financial Times publishes feature on the state of microphysiological systems, highlighting Hesperos

By Hesperos | August 15, 2022 | 0 Comments

Financial Times wrote an excellent feature on microphysiological systems, highlighting Hesperos’ Human-on-a-Chip.

Dr. Kronauge appointed as CEO

By Hesperos | May 26, 2022 | 0 Comments

Hesperos, Inc. appoints new Chief Executive Officer, Dr. James Kronauge I’m excited to join Hesperos as we expand the capabilities of the Human-on-Chip platform enabling drug developers unprecedented insight into specific disease states, especially for rare … Read More

Hesperos Shows Potential for In Vitro Approach to Replace Conventional Animal Efficacy Studies for Rare Neuromuscular Disorders

By Hesperos | April 19, 2022 | 0 Comments

1) Validates use of Human-on-a-Chip system to mimic disease mechanisms of rare autoimmune neuropathies that cannot be replicated in animal models.

2) Efficacy data from microphysiological system supported the authorization of a clinical study (NCT04658472) in 2021 through collaboration with Sanofi.

Hesperos Validates Utility of Human-on-a-Chip® Approach to Model Rare Autoimmune Disease, Myasthenia Gravis

By Hesperos | November 22, 2021 | 0 Comments

Hesperos, Inc is proud to announce Dr. Virginia Smith’s recent publication in Frontiers in Cell and Developmental Biology which validates the Human-on-a-Chip method to model the rare autoimmune disease, Myasthenia Gravis. Read the full press release below: … Read More

Hesperos & Tabula Rasa Awarded $1.9M NIH Grant to investigate preventable Drug-induced Alzheimer’s Disease

By Hesperos | August 27, 2021 | 0 Comments

Hesperos and Tabula Rasa receive $1.9M National Institutes of Health Research Grant Focused on Preventable Drug-Induced Alzheimer’s Disease

Nature Scientific Reports Study Validates Utility of Human-on-a-Chip to Model NAFLD

By Hesperos | June 26, 2021 | 0 Comments

New study published in Nature Scientific Reports validates the utility of Human-on-a-Chip to model Nonalcoholic Fatty Liver Disease (NAFLD)

Pharma Manufacturing Interview with Dr. Michael Shuler on Reducing Animal Testing in Drug Discovery

By Hesperos | May 25, 2021 | 0 Comments
Using Human-on-a-Chip technology to reduce animal testing in drug discovery

Senior Editor with Pharma Manufacturing interviews Hesperos executives Michael Shuler and Nathan Post on the rise of Human-on-a-Chip (HoaC) systems and how they are replacing the need for animal testing in drug discovery.